Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant

NCT05145062 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT05145062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05145062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant
Lead sponsor
Sangamo Therapeutics
Phase
Observational
Overall status
Active, not recruiting
Start date
December 21, 2021
Completion date
July 14, 2038
Enrollment
8 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

blood and lymphatic diseases